Patents by Inventor Wayne To

Wayne To has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
    Publication number: 20250051405
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: July 12, 2024
    Publication date: February 13, 2025
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Factor VIII zwitterionic polymer conjugates
    Patent number: 12214044
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: February 4, 2025
    Assignee: KODIAK SCIENCES INC.
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS
    Publication number: 20240293585
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.
    Type: Application
    Filed: April 17, 2024
    Publication date: September 5, 2024
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Didier G. Benoit, Lane A. Clizbe, Wayne To, Linda J. Zadik, Jeanne M. Pratt
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 12071456
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 27, 2024
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES
    Publication number: 20240197810
    Abstract: The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.
    Type: Application
    Filed: October 19, 2023
    Publication date: June 20, 2024
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Lane A. Clizbe, Didier G. Benoit, Wayne To
  • Multifunctional zwitterionic polymer conjugates
    Patent number: 11819531
    Abstract: The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: November 21, 2023
    Assignee: Kodiak Sciences Inc.
    Inventors: Stephen A. Charles, D. Victor Perlroth, Lane A. Clizbe, Didier G. Benoit, Wayne To
  • MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES
    Publication number: 20230277616
    Abstract: The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.
    Type: Application
    Filed: April 14, 2016
    Publication date: September 7, 2023
    Inventors: Stephen A. Charles, D. Victor Perlroth, Lane A. Clizbe, Didier G. Benoit, Wayne To
  • FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES
    Publication number: 20230173081
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Application
    Filed: February 7, 2023
    Publication date: June 8, 2023
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • Factor VIII zwitterionic polymer conjugates
    Patent number: 11590235
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: February 28, 2023
    Assignee: Kodiak Sciences Inc.
    Inventors: Stephen A. Charles, Daniel Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS
    Publication number: 20210402015
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 30, 2021
    Inventors: Stephen A. CHARLES, Daniel Victor PERLROTH, Didier G. BENOIT, Lane A. CLIZBE, Wayne TO, Linda J. ZADIK, Jeanne M. PRATT
  • Dual PDGF/VEGF antagonists
    Patent number: 11155610
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
    Publication number: 20210277074
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: January 15, 2021
    Publication date: September 9, 2021
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jerrfey L. Cleland
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20210277378
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: January 19, 2021
    Publication date: September 9, 2021
    Inventors: Volker SCHELLENBERGER, Willem P. STEMMER, Nathan C. GEETHING, Wayne TO, Joshua SILVERMAN, Chia-wei WANG, Benjamin SPINK
  • Butyrylcholinesterase zwitterionic polymer conjugates
    Patent number: 11071771
    Abstract: The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: July 27, 2021
    Assignee: Kodiak Sciences Inc.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, Wayne To, Xiaojian Huang, Martin Linsell, Didier Benoit
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES
    Publication number: 20200261590
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Application
    Filed: February 4, 2020
    Publication date: August 20, 2020
    Inventors: Stephen A. Charles, D. Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • DUAL PDGF/VEGF ANTAGONISTS
    Publication number: 20200262905
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Applicant: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Factor VIII zwitterionic polymer conjugates
    Patent number: 10702608
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 7, 2020
    Assignee: KODIAK SCIENCES INC.
    Inventors: Stephen A. Charles, D. Victor Perlroth, Li Song, Martin Linsell, Wayne To, Didier Benoit, James Aggen
  • HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS
    Publication number: 20200171179
    Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 4, 2020
    Inventors: Stephen A. Charles, D. Victor Perlroth, Didier G. Benoit, Lane A. Clizbe, Wayne To, Linda J. Zadik, Jeanne M. Pratt
  • BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES
    Publication number: 20190255155
    Abstract: The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Inventors: D. Victor Perlroth, Stephen A. Charles, Wayne To, Xiaojian Huang, Martin Linsell, Didier Benoit